Infliximab (IFX) is an anti-tumor necrosis factor (TNF)-alpha chimeric monoclonal antibody used in the management of autoimmune inflammatory disorders such as rheumatoid arthritis (RA), psoriasis, Crohn’s disease, and inflammatory bowel disease (IBD). This evidence concerns the gene TNF and psoriasis.